How I cured my dry eyes – A personal story

I’m here to tell you that I’m a living, walking miracle. I am 43 years old and started suffering from severe dry eye syndrome several months ago. My condition was so severe I barely wet the tip of the filter paper on the Schirmer tear test and showed corneal staining along the outer edge of the cornea. I had to use artificial tears every 10-15 minutes, along with night-time eye ointment. My ophthalmologist only wanted to talk about punctal plugs and Restasis. Now, thanks to you guys, I don’t need either one. I started taking the TheraLife eye regimen 2 1/2 weeks ago, along with flaxseed and fish oils. In two weeks or less, I stopped using artificial tears or ointments and haven’t had to use them for three straight weeks and counting. And to make things even more interesting, the air has been a little drier over the time when I started feeling dramatic relief. 

 Thanks Again, 

 Nick. United States

Why do TheraLife Eye capsules work for dry eyes?  

TheraLife® treats dry eyes intra-cellularly to restore balance and end the cycle of dry, itchy red eyes. TheraLife® promotes your cellular functioning to provide natural dry eye relief with your tears. After using TheraLife® Eye capsules, you will once again have an innate ability to produce tears, eliminating inflammation and dryness.

End your reliance on eye drops and restore your comfortable vision. Whether you suffer from watery, dry eyes, blepharitis, meibomian gland dysfunction, chronic and severe dry eyes,

To learn more, click here

Sources of Moisture in the Eyes

Lacrimal glands

The lacrimal gland located in the upper outer quadrant of the eye is responsible for producing tears. This gland produces a lot of tears when you cry or cut an onion.

Conjunctiva

Conjunctiva is a source of eye moisture. Conjunctiva is a network of glands embedded in the white part of the eye. These important glands produce water and mucus, which keep the eye from drying out. Conjunctiva is also under the surface of the eyelids.

Meibomian Oil Glands

Finally, the glands at the edge of the lids produce an oily substance that keeps the eye lubricated. 

When mixed with the water and mucus from the conjunctiva, this tear film on the eye’s surface allows for good vision. Lubricant gets distributed every time a person blinks. They are keeping the eye moist and protected.

What does it mean by Lack of Tears?

The tear production in the eyes tends to slow as a person ages. For women, menopause is one of the primary reasons for dry eyes because there are hormones in the tear. If the tear-producing lacrimal glands don’t make tears as they once did, there will be a problem with the amount of tears. When either of the other two glands slow, the result is dry eye syndrome. 

A lack of tear film on the eye can leave a person feeling burning, grittiness, or eye pain.

Other Causes of Dry Eye Syndrome

In addition to aging, there are many other causes of dry eye syndrome. These include:

• Side effects from antihistamines, blood pressure medicines, or other medications
• Thyroid problems, rheumatoid arthritis, Parkinson’s disease, Sjögren’s syndrome, diabetes, or other underlying conditions
• Exposure to irritating environmental pollutants such as dust, smoke, or pet dander
• Eye surgery
• Contact lens use
• Staring at a computer screen, phone, or television for too long without blinking and replenishing the tear film
• Autoimmune diseases such as Sjogren’s, Lupus has dry eyes. 

 Computer Vision Syndrome

A dry eye syndrome culprit not seen much until the 21st century is known as computer vision syndrome(CVS). CVS is caused by staring at the computer screen for long periods and blinking less. Since the eyes are open more often, they tend to dry out since the lack of blinking does not refresh the eye’s surface with lubricating tears. Symptoms of this new cause include blurry or double vision.

LASIK surgery causing dry eyes.

LASIK surgery, which cuts and shapes your cornea for you to see without prescription glasses, can cause dry eyes. The resulting dry eye can be permanent. If you already have dry eyes, don’t do LASIK surgery.

Traditional ways to Treat Dry Eyes

Treating dry eyes is not only for comfortable vision, but it can also help avoid infections and scarred corneas. The treatment options for dry eye syndrome include:

• Warm compresses
• Gentle eye massage will stimulate the oil glands on the eyelids
• Artificial tears bring temporary relief. Frequent use of eye drops does make dry eyes worse.
• Certain medicines- especially antihistamines.  
• Placement of tear drainage ducts into the tear duct to block excessive tear drainage
• TheraLife products for dry eye syndrome – to restore tear functions inside out.

People with dry eyes opt for a more natural solution -TheraLife especially when eye drops no longer work. 

How TheraLife can help in dry eye relief.

How does TheraLife Eye work?

TheraLife goes directly to the source of the problem of dry eyes-lack of tear production. TheraLife addresses the fundamental cause of dry eyes: underactive tear secretion. By targeting the issue of decreased tear production from the inside out with natural methods, TheraLife promotes the production of the body’s tears without the use of artificial tears, medications, or surgical procedures.

TheraLife Eye Formula

TheraLife Eye is an all-natural, unique proprietary formula. Clinically, TheraLife Eye has proven to work for 80% of first-time users. It works by increasing intracellular metabolism, membrane permeability, and microcirculation of the blood to the eyes. Now the meibomian, lacrimal, and goblet cells that make up the tear glands can secrete their tears naturally, helping to overcome dry eye syndrome issues.  

TheraLife Eye Reduces inflammation.

When the body can produce tears- no more dryness and naturally pain 

Restoration of comfortable vision is possible with TheraLife’s line of all-natural products that address the root cause of dry eye. End reliance on drops or medicine and restore comfortable vision for the eyes with TheraLife.

Get help from TheraLife Today.

Call and talk to a doctor toll-free 1-877-917-1989 US/Canada. International (650) 949-6080. Email to: [email protected]

To purchase, click here

REFERENCES

1. StapletonF , AlvesM , BunyaVY , et al. TFOS DEWS II epidemiology report. Ocul Surf 2017;15:334–65.
2. RolandoM , IesterM , MacrìA , et al. Low spatial-contrast sensitivity in dry eyes. Cornea 1998;17:376–9
3. Benitez-Del-CastilloJ , LabetoulleM , Baudouin C. et al. Visual acuity and quality of life in dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf 2017;15:169–78
4. QchinoM , SchaumbergDry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep 2013;1:51–7
5. WolffsohnJS , AritaR , ChalmersR , et al. TFOS DEWS II diagnostic methodology report. Ocul Surf 2017;15:539–74
6. van SettenG ,LabetoulleM , BaudouinC , et al. Evidence of seasonality and effects of psychrometry in dry eye disease. Acta Ophthalmol 2016;94:499–506
7. NicholsKK , RedfernRL , JacobJT , et al. The TFOS international workshop on contact lens discomfort: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 2013;54:14–19
8. CarntNA , KeayL , NaduvilathT , et al. Risk factors associated with corneal inflammation in soft contact lens daily wear. Invest Ophthalmol Vis Sci 2007;49:4326.
9. RolandoM , CanteraE , MencucciR , et al. The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O board. Int Ophthalmol 2018;38:875–95
10. BaudouinC , MessmerEM , AragonaP , et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol 2016;100:300–6
11. MantelliF , ArguesoFunctions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol 2008;8:477–83
12. CraigJP , TomlinsonImportance of the lipid layer in human tear film stability and evaporation. Optom Vis Sci 1997;74:8–13.
13. RolandoM , RefojoMF , KenyonTear water evaporation and eye surface diseases. Ophthalmologica 1985;190:147–9
14. BraunRJ , King-SmithPE , BegleyCG , et al. Dynamics and function of the tear film in relation to the blink cycle. Prog Retin Eye Res 2015;45:132–.
15. SteppMA , TadvalkarG , HaktR , et al. Corneal epithelial cells function as surrogate Schwann cells for their sensory nerves. Glia 2017;65:851–63
16. AragonaP , Rania L , Puzzolo The role of inflammation, inflammatory cytochines, and ocular surface markers in dry eye disease. In: Benitez Del Castillo JM , Lemp MA , eds. Ocular surface disorders . London: JP Medical Publishing, 2013:55–68.

17. Lemp MA, Baudouin C, Baum J. et al. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf 2007;5:75–92.

17. MusumeciM , BellinM , MalteseA, et al. Chitinase levels in the tears of subjects with ocular allergies. Cornea 2008;27:168–73
18. MusumeciM , AragonaP , BellinM , et al. Acidic mammalian chitinase in dry eye conditions. Cornea 2009;28:667–72
19. ChenZ , TongL , LiZ , et al. Hyperosmolarity-induced codification of human corneal epithelial cells is regulated by JNK MAPK. Invest Ophthalmol Vis Sci 2008;49:539–49
20. SalomonA , DursunD , LiuZ , et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry eye disease. Invest Ophthalmol Vis Sci 2001;42:2283–92.
21. MassingaleML , LiX , VallabhajosyulaM , et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009;28:1023–7
22. KangMH , KimMK , LeeHJ , et al. Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci 2011;26:938–44
23. De PaivaCS , CorralesRM , VillarealAL , et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006;83:526–35
24. BrignoleF , PisellaPJ , GoldschildM , et al. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eye. Invest Ophthalmol Vis Sci 2000;41:1356–63.
25. AragonaP , RolandoTowards a dynamic customised therapy for ocular surface dysfunctions. Br J Ophthalmol 2013;97:955–60.
26. ZakiI , FitzgeraldP , HardyJG , et al. A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man. J Pharm Pharmacol 1986;38:463–6
27. PrabhasawatP , TsengFrequent association of delayed tear clearance in ocular irritation. Br J Ophthalmol 1998;82:666–75
28. AragonaP , SimmonsPA , WangH , et al. Physicochemical properties of Hyaluronic acid-based lubricant eyedrops. Trans Vis Sci Technol 2019;8:2
29. TongL , BeuermanR , SimonyiS , et al. Effects of punctal occlusion on clinical signs and symptoms and on tear cytokine levels in patients with dry eye. Ocul Surf 2016;14:233–41

1. 1. Marsh P , Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999;106:811–6

31. PflugfelderSC , MaskinSL , AndersonB , et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004;138:444–57
32. AragonaP , SpinellaR , RaniaL , et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome. Eur J Ophthalmol 2013;23:368–76
33. RolandoM , VaggeSafety and efficacy of cortisol phosphate in hyaluronic acid vehicle in the treatment of dry eye in Sjogren Syndrome. J Ocul Pharmacol Ther 2017;33:383–90
34. SallK , StevensonOD , MundorfTK , et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye diseaseCsA Phase 3 Study Group. Ophthalmology 2000;107:631–
35. LeonardiA , Van SettenG , AmraneM , et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 2016;26:287–96
36. MoscoviciBK , HolzchuhR , ChiacchioBB , et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea 2012;31:945–9
37. PerezVL , PflugfelderSC , ZhangS , et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf 2016;14:207–15
38. LiN , HeJ , SchwartzCE , et al. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther 2010;26:431–
39. CortinaMS , HeJ , LiN , et al. Neuroprotectin D1 synthesis and corneal nerve regeneration after experimental surgery and treatment with PEDF plus DHA. Invest Ophthalmol Vis Sci 2010;51:804–10
40. RolandoM ,BarabinoS , AlongiS , et al. Topical non-preserved diclofenac therapy for keratoconjunctivitis sicca. Adv Exp Med Biol 2002;506:1237–40.
41. AragonaP , StiloA , FerreriF , et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren’s syndrome patients. Eye (Lond) 2005;19:535–9